January 30 2009 / by Jeff Hilford / In association with Future Blogger.net
Category: Biotechnology Year: 2009 Rating: 7 Hot
There's no actual change in policy from the Obama administration on the stem cell front yet but some exciting things are happening and you can feel the pace picking up. In the past week Geron Technologies announced that they have received FDA clearance to put their GRNOPC1 into clinical human trials and researchers in Spain also announced that they had had success in treating lab rats with significant spinal injuries. While both studies have achieved impressive results in lab animals, a primary difference is that Geron uses embryonic stem cells to derive their hESC oligodendrocyte progenitor cells while the Spanish team used adult stem cells from tissue in the injured rats themselves to get their progenitor cells. Miodrag Stojkovic, who headed up the study done in Spain, said that "we need both adult and embryonic stem cells to understand our body and apply this knowledge in regenerative medicine."
It's worth noting that the success has come with injuries where the spinal cord has been traumatically compromised but not entirely severed. Also, the success in the rat recovery process has been demonstrated in injuries treated within 7-14 days of occurrence. Though there is hope that treatments will be derived for those whose injuries are older, rapid application seems to be key and has also been found effective in treating a variety of neural injuries including stroke and brain trauma.